Epidermal growth factor receptors in intracranial and breast tumours: their clinical significance.
A method to determine the binding of epidermal growth factor (EGF) to the particulate fraction of the cell has been established and evaluated using rat liver, human placenta, and tumours of human breast and brain. Little EGF receptor (EGFR) activity was detected in normal or benign tumour tissues except for meningioma (positive in 95% samples), but EGFR were present in 43% of 131 breast tumours and 75% of 55 primary cerebral tumours. Despite the strong inverse correlation between EGFR activity and oestrogen receptors in breast tumours and a tendency for high levels of EGFR activity to be associated with glioblastoma multiforme, analysis showed that EGFR was of little prognostic significance in patients with tumours of either breast or brain.
Hawkins
R A
RA
University Department of Surgery, Royal Infirmary of Edinburgh, UK.
Killen
E
E
Whittle
I R
IR
Jack
W J
WJ
Chetty
U
U
Prescott
R J
RJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001932:Brain Neoplasms / Q000378:metabolism*; D001943:Breast Neoplasms / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D006801:Humans; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D011379:Prognosis; D011869:Radioligand Assay; D051381:Rats; D013347:Subcellular Fractions / Q000378:metabolism; D013696:Temperature
D066246:ErbB Receptors